Orofacial granulomatosis associated with Crohn's disease: clinical phenotype and response to biologics and Janus kinase inhibitor therapy in a large multi-center cohort.

What To Know

This study pooled records from two UK centers (n=117) and compared clinical features with a large CD control cohort. OFG was linked to younger age at diagnosis and more frequent ileocolonic, upper-GI, and perianal disease.

The authors report that anti-TNF therapies (infliximab, adalimumab), anti-IL-23/12-23 agents (ustekinumab, risankizumab), and the JAK inhibitor upadacitinib produced clinical remission in a notable fraction of patients, often requiring dose escalation.

The study also found that higher circulating anti-TNF drug concentrations were associated with greater odds of response. The report is grounded in the article abstract and patient-record data described by the authors; it does not represent new treatment recommendations.

Discussing therapy changes, dose optimization, or drug-level testing with a treating clinician is appropriate for individual care decisions.